Qualigen Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
QLGN Nasdaq 8731 https://www.qualigeninc.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Qualigen Therapeutics Inc

Qualigen Therapeutics, Inc. Announces management changes. - Sep 26th, 2024 9:10 pm
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Sep 20th, 2024 1:00 pm
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) - Sep 6th, 2024 9:00 pm
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering - Sep 6th, 2024 8:30 pm
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering - Sep 5th, 2024 1:00 pm
Lifecore Biomedical Announces Cooperation Agreement with 22NW - Jul 1st, 2024 12:00 pm
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination - May 30th, 2024 8:00 pm
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - Apr 16th, 2024 11:00 am
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting - Apr 10th, 2024 12:00 pm
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting - Apr 9th, 2024 12:00 pm
QLGN: Dosing Begins in Phase 1 Trial of QN-302… - Nov 27th, 2023 11:14 am
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 - Nov 14th, 2023 9:30 pm
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors - Nov 7th, 2023 1:30 pm
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer - Oct 23rd, 2023 12:30 pm